Tony Berberabe, MPH


Dostarlimab Triplet Shows Antitumor Activity, Tolerability in Ovarian Cancer

March 20th 2021

Dostarlimab plus niraparib and bevacizumab showcased favorable antitumor activity and tolerability in patients with platinum-resistant ovarian cancer.

Enfortumab Vedotin Showcases Impressive Safety, Efficacy in Cisplatin-Ineligible Urothelial Cancer

February 13th 2021

February 12, 2021 - Enfortumab vedotin elicited the highest response rates observed for any regimen examined in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors.

Ruxolitinib Induces Improved Responses in Chronic GVHD

February 12th 2021

February 12, 2021 - Ruxolitinib demonstrated a significantly higher overall response rate compared with best available therapy among adolescent and adult patients with chronic graft-versus-host disease.

Nab-Paclitaxel Noninferior to Docetaxel in Previously Treated NSCLC

January 29th 2021

January 29, 2021 - Nab-paclitaxel proved to be noninferior to docetaxel, having showcased improved progression-free survival, overall survival, and overall response rate in patients with previously treated advanced non–small cell lung cancer.

Axitinib/Octreotide Combo Fails to Improve PFS in Pancreatic NETs

January 17th 2021

January 17, 2021 - Axitinib plus octreotide LAR failed to demonstrate a significant improvement in progression-free survival (PFS) compared with placebo plus octreotide LAR in patients with advanced G1-2 extra-pancreatic neuroendocrine tumors.

Creating a Community Improves Outcomes in Myeloma

January 6th 2021

A community can be defined by any number of characteristics. In Lonial’s case, he has built a community of physicians who’ve come together to treat patients with multiple myeloma.

Pevonedistat/Azacitidine Demonstrates Improved Efficacy Vs Single-Agent Azacitidine in MDS

December 8th 2020

December 8, 2020 — Pevonedistat in combination with azacitidine improved overall survival and prolonged event-free survival compared with azacitidine monotherapy in patients with higher-risk myelodysplastic syndrome.

Belantamab Mafodotin Elicits Deep, Durable Responses in Heavily Pretreated Relapsed/Refractory Myeloma

December 6th 2020

December 6, 2020 — The antibody-drug conjugate belantamab mafodotin continued to showcase efficacy and tolerability in heavily pretreated patients with relapsed/refractory multiple myeloma, inducing durable responses even in those who had previously received 7 or more lines of therapy.

bb21217 Continues to Showcase Durable Responses in Multiple Myeloma

December 5th 2020

December 5, 2020 - The enriched chimeric antigen receptor T-cell therapy bb21217 improved responses and also prolonged duration of response compared with non-enriched CAR T cells in patients with relapsed/refractory multiple myeloma.

Low-Dose Lenvatinib Shows Similar Safety to Standard Dose in RCC, But Noninferiority Cannot Be Claimed

November 7th 2020

A 14-mg dose of lenvatinib showed similar safety to the standard 18-mg dose of the agent, when used in combination with everolimus in the second-line treatment of patients with advanced renal cell carcinoma, but noninferiority could not be confirmed.